SomaLogic doubles sales, trims losses in third quarter

BOULDER — After a rocky second quarter, SomaLogic Inc. (Nasdaq: SLGC), a Boulder-based biotechnology company that went public last year in a merger with a special purpose acquisition company, doubled its year-over-year revenue total in the third quarter, trimmed its net losses and is raising its full-year sales guidance. 

Third quarter 2022 revenues were $41.7 million, up from $20 million in the same period last year. 

Somalogic’s net loss was $32.9 million for the three months ended September 30, or a loss of $0.18 per share, as compared to a loss of $41.4 million, or $0.30 per share, in the…